Abstract P5-08-02: Real-life analysis evaluating 1594 N0/Nmic breast cancer patients for whom treatment decisions incorporated the 21-gene recurrence score result: 5-year KM estimate for breast cancer specific survival with recurrence score results ≤30 is >98%
Salomon M. Stemmer(Tel Aviv University), Nicky Liebermann(Clalit Health Services), Megan Rothney(Sheba Medical Center), Georgeta Fried(Roche (Switzerland)), Noa Ben-Baruch(Kaplan Medical Center), Lior Soussan‐Gutman(Teva Pharmaceuticals (Israel)), Kim L. Isaacs(University of North Carolina at Chapel Hill), M. Steiner(Sheba Medical Center), Steven Shak(Genomic Health (United States)), Shulamith Rizel(Rabin Medical Center), Bella Kaufman(NYU Langone Health), Cecilia Svedman(Lund University), Beatrice Uziely(Hadassah Medical Center), Ella Evron(Sidney Kimmel Comprehensive Cancer Center), SH Klang(Sheba Medical Center), Bella Nisenbaum(Meir Medical Center), D. Geffen(Sheba Medical Center), L Ryvo, Jamal Zidan(Rebecca Sieff Hospital), Ora Rosengarten(Sheba Medical Center)
Cited by 23
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
|Annals of Oncology|2018|1.2k